Stalevo
PreclinicalSmall molecule
Orion Corporation, Orion PharmaStalevo is one of 34 small molecule programs targeting Sleep Disorder. It is currently in Preclinical.
1
Indications
8
Total Trials
0
Active Trials
33
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
43 competitors in Sleep Disorder
#DrugCompanyPhaseTrials
1Diamox
TevaApproved
Livial
PfizerApproved
Rozerem
TakedaApproved
Dayvigo
EisaiApproved
Epidiolex
Jazz PharmaceuticalsApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Kynmobi
SSamson Clinical Operations Pty Ltd
Approved
Nuvigil
NNuvo Research GmbH
Approved
Provigil
NNuvo Research GmbH
Approved
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Parkinson's Disease3 trials
Clinical Study of Stalevo in the Treatment of Early Parkinson's Disease
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04952194·180 enrolled
Sleep Disorder1 trial
Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease
Unknown status·—·N/A·NCT02452606·100 enrolled
1 more indication
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Stalevo. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details